- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Treatment Transitions: Exploring Clinical Responses to Ruxolitinib Monotherapy for Atopic Dermatitis Management
Author(s):
An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.
Video Player is loading.
Video content above is prompted by the following question(s):
- How do the study findings align with your own clinical experiences and observations in managing patients with atopic dermatitis (AD)?
- What additional information would you find valuable to assess the real-world effectiveness of ruxolitinib cream in managing AD, beyond what was presented in the study methodology?
- Please comment on how physician satisfaction has influenced the adoption and integration of ruxolitinib cream in clinical practice.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Understanding the Role of OX40 in Next-Generation Eczema Therapies
Jonathan Silverberg, MD, PhD, MPH on Keeping Up With Rapid AD Developments
The Vicious Cycle of Itch, Stress, and Sleep Loss
Christopher Bunick, MD, PhD, Previews RAD 2025: Raising the Bar in Atopic Dermatitis Care
Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments
Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines
The Future of Pediatric Atopic Dermatitis Treatment and Emerging Therapies
JAK Inhibitors as Flexible, Fast-Acting Option for Refractory AD
Related Content
